CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr. Ausiello, the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Chair of Medicine, Emeritus at Massachusetts General Hospital (MGH), is an internationally acclaimed clinician who brings a wealth of academic and clinical experience in medicine to Seres.
“Dennis is a leader in clinical medicine and a champion of novel approaches to addressing human health. We are honored to have him join Seres as a director,” said Roger Pomerantz, M.D., President, Chief Executive Officer, and Chairman of Seres Therapeutics. “As we continue to progress our lead clinical candidate, SER-109, for the prevention of recurrent Clostridium difficile infection, and advance our other programs towards the clinic, Dennis’ experience will be invaluable. I look forward to collaborating with him as we develop treatments to address diseases that may be impacted by designed microbiome therapies.”
Dr. Ausiello is a nationally recognized leader in academic medicine and was Chief of Medicine at the MGH from 1996 until 2013. He currently serves as Director of the Center for Assessment Technology and Continuous Health (CATCH), a collaboration between MGH and the Massachusetts Institute of Technology that is committed to the discovery and application of new ways to quantitatively measure the human condition (phenotypes) in health and disease. He has made a substantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction, and has published numerous articles, book chapters and textbooks. Previously, Dr. Ausiello served as Chief of the MGH Renal Unit, overseeing its development into one of the most sought-after research and training programs in the world. He also serves on the board of directors of Pfizer.
“Seres has an opportunity to translate the emerging understanding of the microbiome’s role in health into important treatments for patients in need,” said Dr. Ausiello. “I have seen first-hand the escalating toll on patients that Clostridium difficile infection is taking worldwide, and am excited to draw on my own background to help Seres successfully deliver life-changing treatments for this and other serious diseases.”
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome.